home / stock / cmxhf / cmxhf quote
Last: | $178 |
---|---|
Change Percent: | 1.05% |
Open: | $179.875 |
Close: | $176.15 |
High: | $179.875 |
Low: | $176.75 |
Volume: | 300 |
Last Trade Date Time: | 04/30/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$178 | $179.875 | $176.15 | $179.875 | $176.75 | 300 | 04-30-2024 |
$176.15 | $176.15 | $176.15 | $176.15 | $176.15 | 20 | 04-29-2024 |
$175.8 | $183 | $175.8 | $183 | $175.8 | 34 | 04-26-2024 |
$178.45 | $180.725 | $178.45 | $180.725 | $178.45 | 964 | 04-24-2024 |
$176 | $176 | $176 | $176 | $176 | 50 | 04-22-2024 |
$173.25 | $0 | $173.25 | $0 | $0 | 605 | 04-19-2024 |
$173.25 | $173.25 | $173.25 | $173.25 | $173.25 | 140 | 04-18-2024 |
$172.54 | $172.54 | $172.54 | $172.54 | $172.54 | 50 | 04-17-2024 |
$175 | $180 | $175 | $180 | $174.96 | 113 | 04-16-2024 |
$180.75 | $180.75 | $180.75 | $180.75 | $180.75 | 33 | 04-11-2024 |
$188.25 | $188.25 | $188.25 | $188.25 | $188.25 | 3 | 04-10-2024 |
$182.79 | $182.79 | $182.79 | $182.79 | $182.79 | 50 | 04-09-2024 |
$180.53 | $180.53 | $180.53 | $180.53 | $180.53 | 22 | 04-08-2024 |
$180.25 | $184.265 | $180.25 | $184.265 | $180.25 | 40 | 04-05-2024 |
$187.668 | $187.4 | $187.668 | $191 | $187.4 | 160 | 04-04-2024 |
$185.25 | $185.25 | $185.25 | $185.25 | $185.25 | 42 | 04-03-2024 |
$184.35 | $189.7 | $184.35 | $189.7 | $184.35 | 429 | 03-27-2024 |
$187 | $185 | $187 | $187 | $181.29 | 541 | 03-26-2024 |
$182.3 | $182.3 | $182.3 | $182.3 | $182.3 | 300 | 03-25-2024 |
$183.25 | $183.25 | $183.25 | $183.25 | $183.25 | 183 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Csl Ltd Company Name:
CMXHF Stock Symbol:
OTCMKTS Market:
New York, United States (ABN Newswire) - OTC Markets Group Inc. (OTCMKTS:OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced CSL Limited (ASX:CSL) (OTCMKTS:CSLLY), a leading global biotechnology company with a dynamic portfolio of lifesaving medicine...
HATTERSHEIM AM MAIN, Germany , Jan. 24, 2020 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced that the Danish Medicines Council has published its final decision, approving human Alpha 1 Antitrypsin (AAT) therapy and Respreeza® as standard treatment for ...